Title for MeetingAbstracts
Alphabetical listing of titles
Pharmacodynamics of BMS-284756 (B) in Counter-Selecting Resistance in a Hollow-Fiber System (HFS).
Pharmacodynamics of Ceftriaxone against Cephalosporin-Sensitive and -Resistant Enterobacter cloacae In Vivo.
Pharmacodynamics of Faropenem against Streptococcus pneumoniae Assessed In Vitro: Comparisons with Cefuroxime, Ceftriaxone, and High-Dose Amoxicillin.
Pharmacodynamics of FK463 in a Thigh Infection Model with Candida albicans.
Pharmacodynamics of Fluoroquinolones against Streptococcus pneumoniae: Analysis of Phase-III Clinical Trials.
Pharmacodynamics of GAR 936 (GAR) in Experimental Endocarditis due to VanA-type Enterococcus faecium.
Pharmacodynamics of Gatifloxacin against Streptococcus pneumoniae in an In Vitro Pharmacokinetic Model: Impact of AUC:MIC Ratios on Eradication.
Pharmacodynamics of Gemifloxacin (GEM) against Quinolone-Resistant Strains of S. pneumoniae (SP) with Known Resistance Mechanisms.
Pharmacodynamics of Levofloxacin (LVX) Against P. aeruginosa (PA) With Reduced Susceptibility From Different Mex Efflux Pump Systems: Do Elevated MICs Always Predict Reduced In Vivo Efficacy?
Pharmacodynamics of Levofloxacin in a Murine Pneumonia Model: Importance of Peak to MIC Ratio Versus AUC.
Pharmacodynamics of Levofloxacin with Different Organisms: One Size Does Not Fit All.
Pharmacodynamics of Moxifloxacin and Levofloxaxin against Staphylococcus aureus and Coagulase-Negative Staphylococci in an In Vitro Pharmacokinetic Model.
Pharmacodynamics of Moxifloxacin vs Eythromycin against Intracellular LEGIONELLA pneumophilain an In Vitro Kinetic Model.
Pharmacodynamics of Multilamellar Liposomal Nystatin against Experimental Disseminated Candidiasis.
Pharmacodynamics of Nafcillin (NAF), Vancomycin (VAN), Linezolid (LIN), Daptomycin (DAP), Alone and Combination of NAF+VAN and NAF+LIN against MSSA and MRSA in Murine Thigh Infection Model.
Pharmacodynamics of Penicillin in Combination Therapy Using Penicillinase in an In Vitro Kinetic Model.
Pharmacodynamics of Posaconazole (POS) against Aspergillus flavus and Candida albicans Fungal Infections in Mice.
Pharmacodynamics of RWJ-333441 (MC-04,546) when Administered as the L-Aspartyl Prodrug RWJ-333442 (MC-04,699) against Staphylococcus aureus in the Neutropenic Mouse Thigh Infection Model.
Pharmacodynamics of RWJ-54428 (MC-02,479) against Streptococcus pneumoniae.
Pharmacodynamics of Sitafloxacin in Neutropenic Mouse Models of Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Susceptible Staphylococcus aureus (MSSA) Sepsis.
Pharmacodynamics of Telithromycin (HMR 3647) against Respiratory Tract Pathogens In Vitro.
Pharmacodynamics of Telithromycin (TEL) in the Treatment of Community-Acquired Pneumonia (CAP).
Pharmacoeconomic analyses in Japan: are they applicable to policy decision making?.
Pharmacoeconomic Analysis of Amphotericin B Lipid Complex (ABLC) versus Liposomal Amphotericin B (L-AmB) in the Treatment of Fungal Infections.
Pharmacoeconomic analysis of four cephalosporins in the treatment of serious bacterial infections: a randomized comparative study.
Pharmacoeconomic analysis of four treatment options for CMV retinitis in Swiss AIDS patients.
Pharmacoeconomic evaluation of alternative approaches to managing H. pylori-infected ulcer patients following initial therapy.
Pharmacoeconomic Evaluation of Expanding Antenatal HIV Screening in London and Amsterdam.
Pharmacoeconomic Impact of a Pharmacist-Managed Automatic Intravenous (IV) to Oral (PO) Conversion Program.
Pharmacoeconomics and adverse effects of Pneumocystis carinii pneumonia (PCP) therapy.